ADMA Biologics Inc (ADMA) - Total Liabilities
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has total liabilities worth $276.00 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are ADMA Biologics Inc's assets to evaluate the company's liquid asset resilience ratio.
ADMA Biologics Inc - Total Liabilities Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ADMA Biologics Inc assets under control.
ADMA Biologics Inc Competitors by Total Liabilities
The table below lists competitors of ADMA Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Embracer Group AB (publ)
ST:EMBRAC-B
|
Sweden | Skr7.27 Billion |
|
Yunnan Botanee Bio-Technology Group Co Ltd
SHE:300957
|
China | CN¥2.05 Billion |
|
Hycroft Mining Holding Corporation
NASDAQ:HYMC
|
USA | $42.24 Million |
|
Shilpa Medicare Limited
NSE:SHILPAMED
|
India | Rs10.57 Billion |
|
Sineng Electric Co Ltd
SHE:300827
|
China | CN¥6.67 Billion |
|
Tower Bersama Infrastructure Tbk PT
JK:TBIG
|
Indonesia | Rp33.25 Trillion |
|
Centuri Holdings, Inc.
NYSE:CTRI
|
USA | $1.53 Billion |
|
Beijing Fuxing Xiaocheng Electronic Technology Co Ltd
SHE:300139
|
China | CN¥257.53 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down ADMA Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ADMA Biologics Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADMA Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADMA Biologics Inc (2006–2025)
The table below shows the annual total liabilities of ADMA Biologics Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $146.92 Million | +5.20% |
| 2024-12-31 | $139.66 Million | -28.00% |
| 2023-12-31 | $193.98 Million | -1.28% |
| 2022-12-31 | $196.49 Million | +45.46% |
| 2021-12-31 | $135.08 Million | +13.11% |
| 2020-12-31 | $119.42 Million | +18.36% |
| 2019-12-31 | $100.90 Million | +46.00% |
| 2018-12-31 | $69.11 Million | +2.10% |
| 2017-12-31 | $67.69 Million | +140.51% |
| 2016-12-31 | $28.14 Million | +22.93% |
| 2015-12-31 | $22.89 Million | +7.89% |
| 2014-12-31 | $21.22 Million | +103.90% |
| 2013-12-31 | $10.41 Million | +69.72% |
| 2012-12-31 | $6.13 Million | +115461.12% |
| 2011-12-31 | $5.31K | -57.06% |
| 2010-12-31 | $12.36K | -99.86% |
| 2009-12-31 | $8.69 Million | +228.22% |
| 2008-12-31 | $2.65 Million | -81.93% |
| 2007-12-31 | $14.65 Million | 0.00% |
| 2006-12-31 | $14.65 Million | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more